The mission of Chelsea’s Hope is to improve the lives of those affected by Lafora Disease and help accelerate the development of treatments.
Chelsea’s Hope Lafora Children Research Fund is an IRS 501(c)3 non-profit organization. EIN: 27-1008382
Chelsea’s Hope, Post Office Box 348626, Sacramento, CA 95834
Announcing a Q&A Session about Family Support for the Safety Study
/by Christine KellyWe are excited to announce a Q&A Session on Zoom about family support for the Safety Study this coming Monday, October 14th, at 10 am ET. Dr. Souad Messahel will join us to answer families’ questions about visas, travel insurance, health insurance, and accommodations for patients accepted into the safety study.
During the meeting, Dr. Messahel will present all the support materials she has for families and answer our questions. Add the event to your Google Calendar, Outlook Calendar, or Yahoo Calendar. Please find the Zoom invite below.
Please email your questions beforehand to Dr. Kit Donohue with the subject line “Safety Study Q&A Question.”
Can’t make it? No worries! We will record the event and share it with families. Also, after the Q&A, Chelsea’s Hope will update our Safety Study FAQs page with everything we’ve learned.
Chelsea’s Hope is inviting you to a scheduled Zoom meeting.
Topic: Q&A Session about Family Support for the Safety Study
Time: Oct 14, 2024 10:00 AM Eastern Time (US and Canada)
Join Zoom Meeting: https://us06web.zoom.us/j/
Meeting ID: 814 4904 1564
Passcode: 847627
—
One tap mobile
+13092053325,,81449041564#,,,,
+13126266799,,81449041564#,,,,
—
Dial by your location
• +1 309 205 3325 US
• +1 312 626 6799 US (Chicago)
• +1 646 931 3860 US
• +1 929 205 6099 US (New York)
• +1 301 715 8592 US (Washington DC)
• +1 305 224 1968 US
• +1 253 205 0468 US
• +1 253 215 8782 US (Tacoma)
• +1 346 248 7799 US (Houston)
• +1 360 209 5623 US
• +1 386 347 5053 US
• +1 507 473 4847 US
• +1 564 217 2000 US
• +1 669 444 9171 US
• +1 669 900 6833 US (San Jose)
• +1 689 278 1000 US
• +1 719 359 4580 US
Meeting ID: 814 4904 1564
Passcode: 847627
Find your local number: https://us06web.zoom.us/u/
Lafora Body Disease Day 2024
/by Christine KellyThis year’s Lafora Body Disease Day holds special significance. Not only are we in the middle of our first Awareness Campaign, but today would have been Chelsea’s 34th birthday – our namesake and the inspiration for Chelsea’s Hope Lafora Children Research Fund. She, along with all the children we have lost to Lafora disease, is the reason we continue the fight. Keep reading for a message from our founder!
Share How You #FightLafora
We seek to honor all our Lafora warriors and heroes as we continue along the therapeutic journey.
Help us reach a cure by joining in! Here’s how you can raise awareness and fund the ION283 Safety Study for Lafora disease:
Creating awareness helps identify more patients, find partners, and expand our community dedicated to reaching treatments for Lafora disease. So many people don’t know Lafora disease exists. Together, we can change that!
Download and share a graphic:
Let’s honor those we’ve lost and continue to fight for our children facing Lafora disease today. Thank you for your support in raising awareness and funding the Safety Study.
A Note from Linda
As many know, I am the founder of Chelsea’s Hope Lafora Children Research Fund, but my most important role and privilege was being Chelsea’s mom.
October 1st, also deemed Lafora Awareness Day, is Chelsea’s birthday; she would have been 34 years old.
She left this world much too soon, in December 2016, at the age of 26.
I began Chelsea’s Hope 15 years ago as a means to connect Lafora families for support, raise awareness, and fund research for a cure. We have succeeded on these points, and I am so proud to share that this past week, the FDA approved the first-ever patient safety study. This is HUGE news!
Please join me in helping fund this historic and life-changing moment in Chelsea’s Hope history. The families of Chelsea’s Hope are desperate to save their children’s lives.
So many of you have donated to our research pleas over the years, and we are forever grateful! Your generosity has made a huge difference to our success. We have now reached this pivotal juncture of clinical trials and are on the cusp of treatment that could positively change the course of life for Lafora patients.
Please donate, join our team, and/or share our campaign to make history by eradicating Lafora disease and saving the lives of our children!
With gratitude and always maintaining HOPE,
Linda
You can still join the Awareness Campaign as a fundraiser (here’s a video to get you started!) or give to support the Safety Study. Chelsea’s Hope also prepared a toolkit to help and will update our Awareness folder with more graphics you can share.
ION283 Safety Study on ClincialTrials.Gov
/by Christine KellyA Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease – ClinicalTrials.gov
We are thrilled to announce that the ION283 Safety Study information was posted to clinicaltrials.gov. Read the full inclusion and exclusion criteria HERE.
Please share the protocol with your clinicians to determine if your loved one is eligible. The essential eligibility criteria is:
At this time, the study is not enrolling patients. However, they have posted the details for families to prepare. If you or your neurologist contact the UTSW team through the clinicaltrials.gov website, you will receive an email instructing you to contact your country’s patient organization for an application packet that your neurologist must complete. However, the patient organizations have not yet received this application packet. Dr. Minassian and his team are waiting for approval of the application packet by the university. They think the packet will be approved sometime in October.
How will the enrollment process work?
When the packet of information is released, neurologists must complete the information requested, and email the packet to the team at UTSW (that contact email will be provided in the packet). The team at UTSW will keep a record of the order in which the packets arrive based on the timestamp of the email, and they will use that list to accept patients on a first-come, first-serve basis.
Patients will not know what number they are on the list. If they receive a spot in the study, they will be contacted when there are enough funds to enroll them.
We will continue to update our patient community as new information becomes available. If you have questions about the application process, contact our Science Director, Dr. Kit Donohue.
Noventia Statement for the Lafora Community
/by Christine KellyDear Lafora Community,
A few weeks ago we finalized an agreement for the rights to ION283, Ionis’ investigational medicine for the treatment of Lafora disease.
Since its founding, Noventia Pharma, a privately owned European specialty pharmaceutical company, has been committed to advancing research to bring hope to people living with rare diseases, particularly those affecting the CNS.
Noventia will now assume full responsibility for the development of ION283 and we are excited to apply our know-how, expertise, and passion to this project.
Over the coming weeks, Ionis will transfer all materials and data related to ION283 to Noventia. Noventia, together with other stakeholders, will then determine the feasibility of clinical development and the next steps for the program.
Our current objective is to start clinical trials as soon as possible and generate data to evaluate ION283 for potential registration in Europe and the US.
For this reason, Noventia is setting up an International Advisory Board to guide and support our efforts. We aim to work in partnership with the European Medicines Agency, the Food and Drug Administration, and Patient Associations where possible to speed up all these processes. We expect the recently initiated clinical trial at UT Southwestern to continue during this time.
We are grateful for the support, collaboration, and perseverance of the Lafora community. We look forward to working with you to expedite this transition and facilitate the continuation of development activities for ION283.
Sincerely,
Massimo
Massimo Radaelli
President & CEO
Noventia Pharma